122 related articles for article (PubMed ID: 9788773)
1. Antiplatelet effect of Z-335, a new orally active and long-lasting thromboxane receptor antagonist.
Tanaka T; Fukuta Y; Higashino R; Sato R; Nomura Y; Fukuda Y; Ito S; Takei M; Kurimoto T; Tamaki H
Eur J Pharmacol; 1998 Sep; 357(1):53-60. PubMed ID: 9788773
[TBL] [Abstract][Full Text] [Related]
2. Z-335, a new thromboxane A(2) receptor antagonist, prevents arterial thrombosis induced by ferric chloride in rats.
Tanaka T; Sato R; Kurimoto T
Eur J Pharmacol; 2000 Aug; 401(3):413-8. PubMed ID: 10936501
[TBL] [Abstract][Full Text] [Related]
3. Antiplatelet effects of the novel thromboxane A2 receptor antagonist sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)-ethylidene]-6,11- dihydrodibenz[b,e] oxepine-2-carboxylate monohydrate.
Karasawa A; Kawakage M; Shirakura S; Higo K; Kubo K; Ohshima E; Obase H
Arzneimittelforschung; 1991 Dec; 41(12):1230-6. PubMed ID: 1840011
[TBL] [Abstract][Full Text] [Related]
4. The potent inhibition of vapiprost, a novel thromboxane A2 receptor antagonist, on the secondary aggregation and ATP release of human platelets.
Horie S; Yamada M; Satoh M; Noritake S; Hiraishi S; Kizaki K; Kurusu O; Nakahara T; Ishii H; Kazama M
Biol Pharm Bull; 1997 Jun; 20(6):625-31. PubMed ID: 9212979
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological characterization of cinnamophilin, a novel dual inhibitor of thromboxane synthase and thromboxane A2 receptor.
Yu SM; Wu TS; Teng CM
Br J Pharmacol; 1994 Mar; 111(3):906-12. PubMed ID: 8019768
[TBL] [Abstract][Full Text] [Related]
6. Z-335, a thromboxane A2 receptor antagonist, suppresses the progression of arachidonic acid-induced hind limb gangrene in rats.
Tanaka T; Fukuta Y; Fukuda Y; Higashino R; Ito S; Takei M; Tamaki H; Kurimoto T; Suzuki Y
Biol Pharm Bull; 1999 Dec; 22(12):1382-4. PubMed ID: 10746175
[TBL] [Abstract][Full Text] [Related]
7. Antiaggregant and antivasospastic properties of the new thromboxane A2 receptor antagonist sodium 4-[[1-[[[(4-chlorophenyl)sulfonyl]amino]methyl]cyclopentyl] methyl]benzeneacetate.
Lardy C; Rousselot C; Chavernac G; Depin JC; Guerrier D
Arzneimittelforschung; 1994 Nov; 44(11):1196-202. PubMed ID: 7848331
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological characterization of potent, long-acting thromboxane receptor antagonists, SQ 33,261 and SQ 33,552.
Harris DN; Michel IM; Goldenberg HJ; Hartl KS; Allen GT; Steinbacher TE; Schumacher WA; Han WC; Hall SE; Floyd DM
J Pharmacol Exp Ther; 1992 Apr; 261(1):131-7. PubMed ID: 1532833
[TBL] [Abstract][Full Text] [Related]
9. GR32191, a highly potent and specific thromboxane A2 receptor blocking drug on platelets and vascular and airways smooth muscle in vitro.
Lumley P; White BP; Humphrey PP
Br J Pharmacol; 1989 Jul; 97(3):783-94. PubMed ID: 2527074
[TBL] [Abstract][Full Text] [Related]
10. Characteristics of the binding of [3H]-GR32191 to the thromboxane (TP-) receptor of human platelets.
Armstrong RA; Humphrey PP; Lumley P
Br J Pharmacol; 1993 Oct; 110(2):539-47. PubMed ID: 8242228
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological profile of BMS 180,291: a potent, long-acting, orally active thromboxane A2/prostaglandin endoperoxide receptor antagonist.
Ogletree ML; Harris DN; Schumacher WA; Webb ML; Misra RN
J Pharmacol Exp Ther; 1993 Feb; 264(2):570-8. PubMed ID: 8437108
[TBL] [Abstract][Full Text] [Related]
12. Intrinsic activity of the non-prostanoid thromboxane A2 receptor antagonist, daltroban (BM 13,505), in human platelets in vitro and in the rat vasculature in vivo.
Bertolino F; Valentin JP; Maffre M; Grelac F; Bessac AM; Maclouf J; Delhon A; Lévy-Toledano S; Patoiseau JF; Colpaert FC
Br J Pharmacol; 1995 May; 115(1):210-6. PubMed ID: 7647979
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic and pharmacodynamic profiles of vapiprost, a selective, long-lasting thromboxane receptor antagonist, after single and multiple oral administration to healthy volunteers.
Uematsu T; Nagashima S; Mizuno A; Hirano K; Nakashima M
J Clin Pharmacol; 1991 Sep; 31(9):815-22. PubMed ID: 1839540
[TBL] [Abstract][Full Text] [Related]
14. Heterogeneity of thromboxane A2 (TP-) receptors: evidence from antagonist but not agonist potency measurements.
Tymkewycz PM; Jones RL; Wilson NH; Marr CG
Br J Pharmacol; 1991 Mar; 102(3):607-14. PubMed ID: 1364826
[TBL] [Abstract][Full Text] [Related]
15. Distinct effects of z-335, a new thromboxane A2 receptor antagonist, on rabbit platelets and aortic smooth muscle.
Yoshida M; Sato Y; Shimura T; Ohkubo S; Honma S; Tanaka T; Kurimoto T; Nakahata N
Pharmacology; 2007; 79(1):50-6. PubMed ID: 17139194
[TBL] [Abstract][Full Text] [Related]
16. Interspecies differences in thromboxane A2 receptors are distinguished by glibenclamide.
Kemp BK; McPherson GA
Eur J Pharmacol; 1998 Aug; 354(2-3):173-8. PubMed ID: 9754918
[TBL] [Abstract][Full Text] [Related]
17. Novel angiotensin II AT(1) receptor antagonist irbesartan prevents thromboxane A(2)-induced vasoconstriction in canine coronary arteries and human platelet aggregation.
Li P; Fukuhara M; Diz DI; Ferrario CM; Brosnihan KB
J Pharmacol Exp Ther; 2000 Jan; 292(1):238-46. PubMed ID: 10604953
[TBL] [Abstract][Full Text] [Related]
18. Interspecies differences in thromboxane receptors: studies with thromboxane receptor antagonists in rat and guinea pig smooth muscles.
Ogletree ML; Allen GT
J Pharmacol Exp Ther; 1992 Feb; 260(2):789-94. PubMed ID: 1531361
[TBL] [Abstract][Full Text] [Related]
19. Activity of a novel dual thromboxane A(2)receptor antagonist and thromboxane synthase inhibitor (BM-573) on platelet function and isolated smooth muscles.
Rolin S; Dogné JM; Michaux C; Delarge J; Masereel B
Prostaglandins Leukot Essent Fatty Acids; 2001 Aug; 65(2):67-72. PubMed ID: 11545621
[TBL] [Abstract][Full Text] [Related]
20. Labeling of human platelet plasma membrane thromboxane A2/prostaglandin H2 receptors using SQB, a novel biotinylated receptor probe.
Komiotis D; Wencel-Drake JD; Dieter JP; Lim CT; Le Breton GC
Biochem Pharmacol; 1996 Sep; 52(5):763-70. PubMed ID: 8765474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
